Testosterone Replacement Therapy:
The Complete Research Guide
Testosterone replacement therapy (TRT) is the medical treatment for hypogonadism, used by over 2.5 million American men to restore testosterone levels from below 300 ng/dL to an optimal 700–1000 ng/dL range. This guide covers every TRT protocol — cypionate, enanthate, cream, and pellets — with clinical trial data, side effect management, and bloodwork monitoring schedules.
📋 On this page
Overview
What Is Testosterone Replacement Therapy?
Medical Indication
Total testosterone <300 ng/dL on two morning tests + symptoms. Free T or calculated free T provides additional diagnostic clarity when SHBG is elevated.
Normal Range
Total testosterone 300–1,000 ng/dL in adult men. Most TRT clinicians target 600–900 ng/dL for optimal symptom relief without excessive supraphysiological levels.
Age-Related Decline
Testosterone declines approximately 1–2% per year after age 30. By age 70, most men have testosterone levels 35–50% below peak, though symptoms vary widely.
Formulations
Types of Testosterone
The ester attached to the testosterone molecule determines its half-life, injection frequency, and peak/trough profile. Choosing the right formulation is critical for stable levels and quality of life.
Testosterone Cypionate
Half-life: ~8 days | Oil-based injectable. The gold standard in the US. Administered IM or SubQ once or twice weekly. Stable levels, low cost, widely available. Typical dose: 100–200mg/week.
Testosterone Enanthate
Half-life: ~7 days | Nearly identical to cypionate. More common in Europe. Same dosing approach: 100–200mg/week IM or SubQ split 1–2x/week. Interchangeable for most protocols.
Testosterone Propionate
Half-life: ~2 days | Requires every-other-day (EOD) or daily injection for stable levels. Faster-acting and quicker to clear. Used by some to minimize side effects. Water-based version (Aquatest) also available.
Testosterone Cream / Gel
Applied daily | Convenient but inconsistent absorption. DHT conversion is higher with scrotal application. Transfer risk to partners and children. Examples: AndroGel, Testim, compounded creams. 50–100mg/day typical.
Testosterone Pellets
Half-life: 3–6 months | Subcutaneously implanted pellets (Testopel) release testosterone steadily. Inserted every 3–6 months. Convenient but cannot be adjusted after implant. Minor surgical procedure required.
Oral Testosterone (Jatenzo)
FDA approved 2019 | Testosterone undecanoate capsule taken with food twice daily. Avoids first-pass liver metabolism via lymphatic absorption. Elevated BP in some users. Less common due to cost.
Clinical Protocol
Typical TRT Protocol
A well-designed TRT protocol goes beyond testosterone alone. Managing co-medications and injection frequency is key to stable levels and minimizing side effects.
| Component | Drug / Compound | Dose Range | Frequency | Purpose |
|---|---|---|---|---|
| Testosterone | Cypionate or Enanthate | 100–200mg | 1–2x/week (SubQ preferred) | Primary androgen replacement |
| Fertility Preservation | HCG (Human Chorionic Gonadotropin) | 250–500 IU | 2–3x/week | Maintain testicular function, preserve fertility, prevent atrophy |
| Aromatase Inhibitor | Anastrozole or Exemestane | 0.25–0.5mg | 2x/week (if needed) | Control estrogen elevation — only if E2 symptomatic + elevated |
| Donation / Hematocrit | Therapeutic phlebotomy | 1 unit blood | As needed | Manage hematocrit elevation (>52%) |
Protocol Startup: The Timeline
Baseline Bloodwork (Week 0)
Total T, free T, estradiol (sensitive), SHBG, LH, FSH, CBC, CMP, lipids, PSA. Two morning tests before starting. Fertility workup (semen analysis) if applicable.
Initiation (Weeks 1–6)
Start testosterone at 100mg/week SubQ. Add HCG if desired. Adjust frequency and dosing. Note: testosterone levels require 4–6 weeks to stabilize. Do not judge efficacy too early.
First Follow-Up Labs (Week 6)
Check total T, free T, estradiol, hematocrit. Assess symptom response. Adjust dose if trough levels are still low (<500 ng/dL). Draw labs at trough (just before next injection).
3-Month Check (Week 12)
Full panel: T, free T, E2, CBC, lipids, PSA. Evaluate symptoms. Finalize protocol. Most patients achieve stable levels and symptom resolution by this point.
Maintenance (Every 6 Months)
Ongoing monitoring every 6 months once stable. Annual PSA for men over 40. Donate blood if hematocrit creeps above 52%. Continue HCG if fertility is a priority.
Clinical Outcomes
What the Research Shows: TRT Results
Data from published clinical trials and meta-analyses examining TRT in hypogonadal men. Results represent average outcomes — individual response varies.
Testosterone Level Changes
Symptom & Body Composition Improvements
Safety Profile
Side Effects & How to Manage Them
TRT has a well-characterized safety profile. Most side effects are dose-dependent and manageable with proper monitoring. Incidence data from pooled clinical trials.
Lab Monitoring
Bloodwork: What to Test & When
Consistent lab monitoring is non-negotiable on TRT. These are the key markers to track and what optimal ranges look like.
Monitoring Schedule
| Time Point | Labs Required | Key Decisions |
|---|---|---|
| Baseline (Before TRT) | Full panel: T, free T, E2, SHBG, LH, FSH, CBC, CMP, lipids, PSA | Confirm diagnosis; rule out contraindications |
| 6 Weeks | Total T (trough), free T, E2 (sensitive), hematocrit | Dose adjustment; assess E2 and hematocrit |
| 3 Months | Full panel (skip LH/FSH): T, free T, E2, CBC, lipids, PSA | Finalize protocol; long-term safety check |
| Every 6 Months | T, free T, E2, CBC, lipids | Ongoing safety monitoring; donate blood if Hct high |
| Annually (40+) | Full panel including PSA, digital rectal exam | Prostate health; cardiovascular risk review |
Comparative Options
TRT vs. Natural Alternatives
TRT is not the only option for men with low testosterone. Here's how it compares to alternatives that preserve the HPG axis.
| Approach | T Increase | HPG Axis | Fertility | Best For |
|---|---|---|---|---|
| TRT (Testosterone Cypionate) | +++ (300→800+ ng/dL) | Suppressed | Preserved with HCG | Confirmed hypogonadism, symptom relief priority |
| Enclomiphene | ++ (~175% increase) | Intact (stimulated) | Maintained | Younger men, fertility preservation, secondary hypogonadism |
| HCG Monotherapy | ++ (moderate) | Intact (LH mimicry) | Maintained | Men wanting testicular stimulation without T shutdown |
| Lifestyle Optimization | + (10–15%) | Intact | Maintained | Borderline T, addressing root causes (sleep, obesity, stress) |
| Clomiphene (Clomid) | ++ (moderate) | Intact (stimulated) | Maintained | Fertility-focused; note: contains zuclomiphene (estrogenic isomer) |
Enclomiphene Guide →
The trans-isomer of clomiphene that raises testosterone ~175% while preserving the HPG axis and fertility. Ideal for secondary hypogonadism and younger men.
HCG Guide →
Complete guide to HCG for TRT adjunct and monotherapy. Protocols, dosing, fertility impact, and how FDA compounding changes affect access.
Summary
Key Takeaways
✅ What We Know
- TRT reliably restores testosterone to physiological ranges in hypogonadal men
- Libido, energy, mood, and body composition improve significantly vs. placebo in confirmed hypogonadism
- HCG co-administration preserves testicular function and fertility during TRT
- SubQ injection frequency (1–2x/week) produces stable T levels equivalent to IM
- TRAVERSE Trial (2023): TRT does not increase major cardiovascular events in hypogonadal men
- Hematocrit elevation is manageable with regular monitoring and therapeutic phlebotomy
- Bone mineral density and lean mass improve significantly over 12+ months
- AI (aromatase inhibitors) are only needed if estradiol is symptomatic and elevated
⚠️ What We Don't Know
- Long-term cardiovascular outcomes (20+ years) — most trials are 1–3 years
- Optimal target T range — whether 700 ng/dL is significantly better than 500 ng/dL for symptoms
- Whether TRT reverses the causes of hypogonadism or simply manages symptoms
- Long-term prostate safety — evidence suggests no increase in prostate cancer, but very long-term data limited
- Full impact on cognitive function — some studies show modest improvement, others show no effect
- Whether TRT-induced erythrocytosis truly increases VTE risk to the same degree as other causes
- Optimal duration of therapy — lifetime treatment vs. intermittent cycles not well studied
🛒 Recommended Products for TRT
Practical supplies for self-administered TRT protocols and supporting supplementation.
Affiliate links help support HighPeptides at no extra cost to you.
TRT + Sleep: A Two-Way Relationship
Testosterone is primarily synthesized overnight during sleep. A single night of sleep deprivation can drop testosterone levels by 10–15%. Beyond low T, TRT itself carries two sleep-specific risks you need to monitor: sleep apnea worsening (testosterone increases upper airway muscle relaxation) and nocturia (the need to urinate at night, fragmenting sleep). Screen for both at baseline.
The ROI math is simple: if you're sleeping 5–6 hours, you're suppressing overnight testosterone synthesis regardless of what you're injecting. Optimizing sleep isn't optional for TRT users — it's part of the protocol.
→ Sleep Optimization for TRT & Peptide UsersWant the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →